1. Cancer statistics;Siegel;CA Cancer J. Clin.,2020
2. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: results from the Phase I KEYNOTE-001 Study;Garon;J. Clin. Oncol.,2019
3. Noone A.M., Howlader N., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J., Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2, (n.d.).
4. Real-world effectiveness of systemic agents approved for advanced non-small cell LungCancer : a SEER–medicare analysis;Owonikoko;Oncologist.,2013
5. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann. Oncol.,2018